CambridgeAn independent panel judged the drug couldn’t win.
Volrustomig couldn’t beat Keytruda, the oncology benchmark every rival drug must clear first.
Keytruda earned its maker $31.7 billion in 2025, the standard every challenger is measured against.
Keytruda’s patents expire in 2028, and no confirmed successor drug exists yet.
Sources: Yahoo